Skip to content

Nevada Medicaid

Does Nevada Medicaid cover Wegovy for Liver Disease (MASH)?

Yes. Nevada Medicaid covers Wegovy for liver disease (MASH) with prior authorization. Other policy requirements and your plan's benefits also apply.

Policy on file; the document isn't available to view online yet.

  • Medicaid: Covered (preferred drug). See the qualification pathways below.

Earliest policy review June 3, 2026. How we verify · Check your exact plan

Full requirements: Wegovy for Liver Disease (MASH) (1 plan type)

Applies to Medicaid plans.

Covered (preferred drug)

Qualification pathways

You can qualify through any one of these.

Initial Approval — MASH

All of:

  • Recipient is 18 years of age or older
  • Diagnosis of noncirrhotic MASH with fibrosis stage 2 or 3 confirmed by liver biopsy, VCTE (e.g., FibroScan), or MRE (submission of medical records required)
  • Recipient does not have any contraindications to Wegovy (e.g., personal or family history of MTC, MEN 2, or hypersensitivity)
  • Recipient is not currently utilizing another GLP-1 therapy
  • Prescriber attestation that medication is being prescribed in conjunction with diet and exercise

Recertification — MASH

All of:

  • Documentation of positive clinical response to therapy

Plus any one of:

  • Recipient is being prescribed the FDA-recommended maintenance dose of 2.4mg weekly
  • Prescriber has indicated dose was decreased to 1.7mg weekly due to intolerance

Documentation to bring

  • Medical records confirming noncirrhotic MASH diagnosis with fibrosis stage 2 or 3 (via liver biopsy, VCTE/FibroScan, or MRE)
  • Documentation that recipient is 18 years of age or older
  • Documentation that recipient has no contraindications to Wegovy (e.g., no personal or family history of MTC or MEN 2, no hypersensitivity)
  • Documentation that recipient is not currently on another GLP-1 therapy
  • Prescriber attestation that medication is prescribed in conjunction with diet and exercise
  • For recertification: documentation of positive clinical response to therapy
  • For recertification: documentation of current dose (2.4mg weekly or 1.7mg weekly with intolerance notation)

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 12 months
  • Renewal: Documentation of positive clinical response to therapy required. Recipient must be prescribed FDA-recommended maintenance dose of 2.4mg weekly, OR prescriber has indicated dose was decreased to 1.7mg weekly due to intolerance.
  • Renewal: Staying on a maintenance dose of at least 1.7 mg.

Not covered when

  • Decompensated cirrhosis (exclusion criterion from Rezdiffra section context; Wegovy criteria require noncirrhotic MASH)
  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple endocrine neoplasia syndrome type 2 (MEN 2)
  • Hypersensitivity to semaglutide or any component of Wegovy
  • Current use of another GLP-1 therapy

Policy note: This document is Nevada Medicaid (Medicaid Services Manual, Appendix A). Wegovy is the preferred MASH agent — Rezdiffra (resmetirom) requires prior failure, intolerance, or contraindication to Wegovy, or specialist justification that Wegovy would be ineffective. The Wegovy MASH criteria do NOT include a BMI requirement. The document does not address Wegovy for weight loss or cv risk reduction indications. Rezdiffra (resmetirom) is documented in this section but is not an in-scope GLP-1 medication; no criteria entry is emitted for it. DUR Board last reviewed: October 16, 2025. Document effective date: January 5, 2026.

Policy effective January 5, 2026 · verified June 3, 2026 · source: Msm 1200 26 04 06

Open on its own page →

Questions people ask
Does Nevada Medicaid cover Wegovy?
Yes. Nevada Medicaid covers Wegovy for liver disease (MASH) with prior authorization. Other policy requirements and your plan's benefits also apply.
How long does a Wegovy approval last with Nevada Medicaid?
Liver Disease (MASH) — Applies to Medicaid plans. Initial approval: 6 months. Renewal: every 12 months.
What does Nevada Medicaid require to renew Wegovy?
Liver Disease (MASH) — Applies to Medicaid plans. Documentation of positive clinical response to therapy required. Recipient must be prescribed FDA-recommended maintenance dose of 2.4mg weekly, OR prescriber has indicated dose was decreased to 1.7mg weekly due to intolerance. Staying on a maintenance dose of at least 1.7 mg.
How current is this information?
The oldest review date among the policies on this page is June 3, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under Nevada Medicaid: Mounjaro, Ozempic, Zepbound

Wegovy under other plans: Elevance Health, Molina Healthcare, Alabama Medicaid, California Medicaid, Clover Health, Colorado Medicaid, Connecticut Medicaid, Delaware Medicaid

All insurance plans · All medications

Summary of Nevada Medicaid's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.